OncLive® On Air S16 Ep14: Pumitamig Represents Potential Immunotherapy Strategy for TNBC: With Sarah Sammons, MD
Feb 26, 2026
Sarah Sammons, MD, an associate director at Dana-Farber and Harvard faculty, outlines pumitamig, a bispecific PD-L1/VEGF-A antibody. She explains the drug’s mechanism and rationale. She reviews phase 2 trial design, strong response rates, safety signals, and plans for a phase 3 registrational study. She also places pumitamig among emerging immunotherapy and ADC strategies for triple-negative breast cancer.
AI Snips
Chapters
Transcript
Episode notes
Bispecific PD-L1 and VEGF‑A Mechanism
- Pumitamig is a bispecific antibody that targets PD-L1 and VEGF-A to combine checkpoint blockade with anti-angiogenic effects.
- The dual mechanism aims to restore T-cell function, normalize tumor vasculature, and overcome VEGF-linked checkpoint resistance.
Global Phase II Design And Chemo Backbones
- The global Phase II was randomized, multi-cohort, and enrolled first- or second-line metastatic TNBC regardless of PD-L1 status to test safety with multiple chemo backbones.
- Cohorts compared dose schedules and combined pumitamig with nab-paclitaxel, paclitaxel, gemcitabine, carboplatin, or eribulin to plan a phase III.
High Response Rates Including PD‑L1 Negative Patients
- Cohort 1 showed a confirmed objective response rate of 61.5% (unconfirmed 72%) and a 92.3% disease control rate among 39 evaluable patients.
- Response rates were identical in PD-L1–positive and PD-L1–negative patients, suggesting activity in immunotherapy-ineligible tumors.